Rosenbaum David P.

Avg. Two Year Performance

No purchase track record

28% Avg. Sale Return

13% Compound

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	5%	(5%)	16%	7%	28%
Sale Success Rate	9 of 19	9 of 19	8 of 19	7 of 19	7 of 19

Ardelyx, Inc.

Drugs » Biotechnology

Chief Development Officer:

Holdings: 582.72K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--